Lite Strategy (LITS) Other Operating Expenses (2016 - 2026)
Lite Strategy (LITS) posted quarterly Other Operating Expenses of -$23.7 million for Q1 2026, down 820.87% year-over-year from $3.3 million in Q1 2025, and up 23.07% quarter-over-quarter from -$30.8 million in Q4 2025.
Lite Strategy (LITS) Other Operating Expenses (2016 - 2026) Analysis & Trends
Lite Strategy's Other Operating Expenses history runs 9 years deep, the most recent figure standing at -$23.7 million for Q1 2026.
- In Q1 2026, Other Operating Expenses fell 820.87% year-over-year to -$23.7 million; the TTM figure through Mar 2026 stood at -$58.1 million (down 2704.25% YoY), while the FY2025 annual figure was $500000.0, changed N/A from the prior year.
- Other Operating Expenses for Q1 2026 stood at -$23.7 million, up from -$30.8 million in the prior quarter.
- The five-year high for Other Operating Expenses was $8.5 million in Q4 2024, with the low at -$30.8 million in Q4 2025.
- The 3-year median for Other Operating Expenses is -$5.8 million (2024), against an average of -$10.0 million.
- The sharpest annual moves came in 2025 and 2026: Other Operating Expenses surged 54.55% in 2025, then slumped 820.87% in 2026.
- Lite Strategy's Other Operating Expenses stood at $8.5 million in 2024, then sank by 462.04% to -$30.8 million in 2025, then advanced by 23.07% to -$23.7 million in 2026.
- Business Quant data shows LITS's Other Operating Expenses at -$23.7 million in Q1 2026, -$30.8 million in Q4 2025, and -$3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.69 Mn |
| Dec 31, 2025 | -30.80 Mn |
| Sep 30, 2025 | -3.64 Mn |
| Mar 31, 2025 | -2.57 Mn |
| Dec 31, 2024 | 8.51 Mn |
| Sep 30, 2024 | -8.01 Mn |
| Mar 31, 2021 | 405,000.00 |
| Dec 31, 2020 | 494,000.00 |
| Sep 30, 2020 | 509,000.00 |
| Jun 30, 2020 | 482,000.00 |
| Mar 31, 2020 | 860,000.00 |
| Dec 31, 2019 | 641,000.00 |
| Sep 30, 2019 | 688,000.00 |
| Jun 30, 2019 | 1.10 Mn |
| Mar 31, 2019 | 1.16 Mn |
| Dec 31, 2018 | 1.01 Mn |
| Sep 30, 2018 | 989,000.00 |
| Jun 30, 2018 | 1.11 Mn |
| Mar 31, 2018 | 930,000.00 |
| Dec 31, 2017 | 728,000.00 |